The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| APGE | +8.74% | N/A | N/A | +167% |
| S&P | +19.89% | +109.18% | +15.89% | +52% |
Apogee Therapeutics, Inc. operates as a biotechnology company. It offers treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications. The company was founded in February 2022 and is headquartered in Waltham, MA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.40M | -1011.1% |
| Market Cap | $2.59B | 76.7% |
| Market Cap / Employee | $13.19M | 0.0% |
| Employees | 196 | 0.0% |
| Net Income | -$66.10M | -95.5% |
| EBITDA | -$72.77M | -65.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $124.19M | -59.6% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $6.82M | 184.0% |
| Short Term Debt | $4.03M | 139.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -32.59% | -7.1% |
| Return On Invested Capital | -25.05% | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$62.80M | -114.0% |
| Operating Free Cash Flow | -$62.03M | -111.7% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 4.30 | 3.61 | 3.10 | 3.84 | 33.77% |
| Price to Tangible Book Value | 4.30 | 3.61 | 3.10 | 3.84 | 33.77% |
| Enterprise Value to EBITDA | -48.13 | -28.83 | -26.60 | -28.08 | -20.23% |
| Return on Equity | -25.6% | -33.2% | -27.9% | -34.1% | 27.68% |
| Total Debt | $12.14M | $11.83M | $11.82M | $10.85M | 165.61% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
